A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer
- 18 April 2023
- journal article
- review article
- Published by Springer Nature in Medical Oncology
- Vol. 40 (5) , 1-20
Abstract
Lung cancer is amongst the most pervasive malignancies having high mortality rates. It is broadly grouped into non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The concept of personalized medicine has overshadowed the conventional chemotherapy given to all patients with lung cancer. The targeted therapy is given to a particular population having specific mutations to help in the better management of lung cancer. The targeting pathways for NSCLC include the epidermal growth factor receptor, vascular endothelial growth factor receptor, MET (Mesenchymal epithelial transition factor) oncogene, Kirsten rat sarcoma viral oncogene (KRAS), and anaplastic lymphoma kinase (ALK). SCLC targeting pathway includes Poly (ADP-ribose) polymerases (PARP) inhibitors, checkpoint kinase 1 (CHK 1) pathway, WEE1 pathway, Ataxia Telangiectasia and Rad3-related (ATR)/Ataxia telangiectasia mutated (ATM), and Delta‐like canonical Notch ligand 3 (DLL-Immune checkpoint inhibitors like programmed cell death protein 1 (PD-1)/ programmed death-ligand 1 (PD-L1) inhibitors and Cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) blockade are also utilized in the management of lung cancer. Many of the targeted therapies are still under development and require clinical trials to establish their safety and efficacy. This review summarizes the mechanism of molecular targets and immune-mediated targets, recently approved drugs, and their clinical trials for lung cancer.Keywords
This publication has 138 references indexed in Scilit:
- Genomic Deregulation of the E2F/Rb Pathway Leads to Activation of the Oncogene EZH2 in Small Cell Lung CancerPLOS ONE, 2013
- Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatmentCancer Management and Research, 2013
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunityCurrent Opinion in Immunology, 2012
- EML4-ALK Fusion Gene in Korean Non-Small Cell Lung CancerJournal of Korean Medical Science, 2012
- Review: Angiogenesis inhibitors in the treatment of non-small cell lung cancerTherapeutic Advances in Medical Oncology, 2009
- Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future DirectionsThe Oncologist, 2008
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- Differential disruption of cell cycle pathways in small cell and non-small cell lung cancerBritish Journal of Cancer, 2006
- Vascular Endothelial Growth Factor Expression in Stage I Non-Small Cell Lung Cancer Correlates With Neoangiogenesis and a Poor PrognosisAnnals of Surgical Oncology, 2001